Entropy Neurodynamics (ASX:ENP) announced a milestone in its clinical trial investigating TRP-8803, an intravenous formulation of psilocin, for the treatment of binge eating disorder.
The company has completed the full enrolment of the first cohort in this trial, which is being conducted in partnership with Swinburne University.
The trial aims to recruit a total of 12 patients divided into two six-person cohorts to evaluate the safety, tolerability, and efficacy of the treatment alongside supportive therapy.
According to the update, "Cohort 1 recruitment complete with 6 patients enrolled in the study."
Within this group, two patients have already completed both dosing sessions, while the remaining four are currently in the baseline assessment phase or scheduled for their first infusion.